ES2536841T3 - Derivados de 2H-piridazin-3-onas, su preparación y su utilización como inhibidores de la SCD-1 - Google Patents

Derivados de 2H-piridazin-3-onas, su preparación y su utilización como inhibidores de la SCD-1 Download PDF

Info

Publication number
ES2536841T3
ES2536841T3 ES10742811.2T ES10742811T ES2536841T3 ES 2536841 T3 ES2536841 T3 ES 2536841T3 ES 10742811 T ES10742811 T ES 10742811T ES 2536841 T3 ES2536841 T3 ES 2536841T3
Authority
ES
Spain
Prior art keywords
oxo
methyl
pyridazin
piperidin
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10742811.2T
Other languages
English (en)
Spanish (es)
Inventor
Elisabeth Dupont-Passelaigue
Samuel Mialhe
Jean-Pierre Rieu
Didier Junquero
Karine Valeille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Application granted granted Critical
Publication of ES2536841T3 publication Critical patent/ES2536841T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES10742811.2T 2009-08-05 2010-08-05 Derivados de 2H-piridazin-3-onas, su preparación y su utilización como inhibidores de la SCD-1 Active ES2536841T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0955504A FR2948939B1 (fr) 2009-08-05 2009-08-05 Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR0955504 2009-08-05
PCT/EP2010/061426 WO2011015629A1 (en) 2009-08-05 2010-08-05 Derivatives of 2h pyridazin- 3 -ones, their preparation and their use as scd-1 inhibitors

Publications (1)

Publication Number Publication Date
ES2536841T3 true ES2536841T3 (es) 2015-05-29

Family

ID=41582079

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10742811.2T Active ES2536841T3 (es) 2009-08-05 2010-08-05 Derivados de 2H-piridazin-3-onas, su preparación y su utilización como inhibidores de la SCD-1

Country Status (10)

Country Link
US (1) US8946225B2 (cg-RX-API-DMAC7.html)
EP (1) EP2462121B1 (cg-RX-API-DMAC7.html)
JP (1) JP5901520B2 (cg-RX-API-DMAC7.html)
AR (1) AR077715A1 (cg-RX-API-DMAC7.html)
ES (1) ES2536841T3 (cg-RX-API-DMAC7.html)
FR (1) FR2948939B1 (cg-RX-API-DMAC7.html)
HU (1) HUE025513T2 (cg-RX-API-DMAC7.html)
PL (1) PL2462121T3 (cg-RX-API-DMAC7.html)
TW (1) TW201109313A (cg-RX-API-DMAC7.html)
WO (1) WO2011015629A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
CA2850836A1 (en) * 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
US9238658B2 (en) 2011-12-06 2016-01-19 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
WO2013085957A1 (en) * 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
CN114805540A (zh) 2015-09-18 2022-07-29 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN117777121A (zh) 2016-10-24 2024-03-29 詹森药业有限公司 化合物及其用途
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
SG11202108079RA (en) 2019-01-24 2021-08-30 Yumanity Therapeutics Inc Compounds and uses thereof
EA202192047A1 (ru) * 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN117164524A (zh) * 2022-09-06 2023-12-05 杭州师范大学 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005011653A2 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
BRPI0507518A8 (pt) * 2004-02-09 2015-12-01 Nissan Chemical Ind Ltd Inibidor de hiperplasia vascular da íntima
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP4984701B2 (ja) * 2006-07-18 2012-07-25 富士ゼロックス株式会社 Ledプリントヘッドの製造方法
JP4695565B2 (ja) * 2006-08-21 2011-06-08 株式会社リコー 画像形成装置
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
DE602008003586D1 (de) 2007-08-08 2010-12-30 Graceway Pharmaceuticals Llc Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus

Also Published As

Publication number Publication date
PL2462121T3 (pl) 2015-07-31
US8946225B2 (en) 2015-02-03
FR2948939A1 (fr) 2011-02-11
EP2462121A1 (en) 2012-06-13
US20120178678A1 (en) 2012-07-12
TW201109313A (en) 2011-03-16
HUE025513T2 (hu) 2016-05-30
WO2011015629A1 (en) 2011-02-10
JP2013501031A (ja) 2013-01-10
FR2948939B1 (fr) 2013-03-22
JP5901520B2 (ja) 2016-04-13
EP2462121B1 (en) 2015-02-18
AR077715A1 (es) 2011-09-14

Similar Documents

Publication Publication Date Title
ES2536841T3 (es) Derivados de 2H-piridazin-3-onas, su preparación y su utilización como inhibidores de la SCD-1
JP5224543B2 (ja) 新規なスピロオキシインドール化合物及びこれを含有する医薬
EP3022184B1 (en) Substituted benzene compounds
JP5599788B2 (ja) トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用
AU2017339249A1 (en) Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
IE912589A1 (en) Substituted bicyclic bis-aryl compounds, their preparation¹and pharmaceutical compositions containing them
WO2011114148A1 (en) 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
EP0178189B1 (en) Pyridazinone derivatives, their preparation and use
SK327692A3 (en) Aromatic amidine derivatives and anticoagulant agent or agent useful for prophylaxy or treatment of thrombosis or embolism
JP2013521291A (ja) Cb2受容体を選択的に調節するテトラゾール化合物
CN112805062B (zh) 作为Trk抑制剂的咪唑并[1,2-b]哒嗪类
EP2758058B1 (en) Substituted pyrimidines
ES2398462T3 (es) Compuestos químicos
EP2903982B1 (en) New pyrrolidine derivatives and their use as acetyl-coa carboxylase inhibitors
US8912183B2 (en) Substituted pyridazine derivatives
EP2997024B1 (en) Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
EP2986604A1 (en) Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
KR20250086658A (ko) 포스포라미데이트 화합물 및 이의 용도
TW200800895A (en) Novel compounds
AU2019362468B2 (en) Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators
EP2785690B1 (en) Piperidine derivatives, pharmaceutical compositions and uses thereof
BRPI0613563A2 (pt) novos derivados de piperidina
KR20130010784A (ko) 메틸리덴-헤테로싸이클릭 화합물